TMCI · Treace Medical Concepts, Inc. · Metrics
Market Cap
$289.73M
Shares
65.03M
TMCI metrics
73 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$4.51
Market cap
$289.73M
Price action
20 metricsPrice change (1W)
-10.9%
Price change (30D)
-3.5%
Price change (3M)
+11.3%
Price change (6M)
+222.2%
Price change (YTD)
+77.6%
Price change (1Y)
-37.9%
Trailing year
Price change (5Y)
-84.1%
52-week high
$7.44
52-week low
$1.20
Change from 52-week high
-41.5%
Change from 52-week low
+262.5%
Annualized volatility
87.2%
Annualized volatility (3M)
76.8%
Beta
1.6
RSI (14D)
44.3
Price vs SMA 50
-2.7%
Price vs SMA 200
+47.9%
Avg volume (3M)
628,125
Relative volume
0.4
Average dollar volume
$2.74M
Company
3 metricsSector
Healthcare
Industry
Medical Devices
Shares outstanding
65.03M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
1.5×
reciprocal yield 67.7%
EV / EBITDA
—
EV / EBIT
—
P / sales
1.4×
reciprocal yield 70.9%
P / book
4.3
reciprocal yield 23.4%
FCF yield
-8.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-20.5%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
2.4×
reciprocal yield 41.8%
EV / revenue historical average (5Y)
4.6×
reciprocal yield 21.6%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-07
Profitability
9 metricsGross margin
79.5%
Operating margin
-26.2%
Trailing 12 months
Net margin
-29.0%
Gross profit (TTM)
$163.12M
Operating profit (TTM)
−$53.72M
Net income (TTM)
−$59.52M
Trailing 12 months
Diluted EPS (TTM)
$-0.92
FCF margin
-12.2%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-4.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$205.31M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.2%
Year over year · more shares
Revenue CAGR (3Y)
+14.5%
Revenue CAGR (5Y)
+30.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-87.9%
Return on assets
-32.9%
Debt / equity
0.9
Current ratio
2.9
EBITDA (TTM)
−$45.35M
Free cash flow (TTM)
−$25.05M
Quick ratio
1.9
Interest coverage
-9.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$13.59M
Latest balance sheet
Cash & equivalents
$12.61M
Total assets
$181.06M
Total debt
$59.21M
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$14.58M
Capital expenditures (TTM)
$10.47M
R&D (TTM)
$18.22M
SG&A (TTM)
—
Stock compensation (TTM)
$30.05M
R&D / revenue
8.9%
Stock compensation / revenue
14.6%
Ownership (13F)
3 metrics13F filers
116
13F filer change QoQ
-2
Institutional ownership
49.1%
Short interest
3 metricsShort interest
2.4%
Latest settlement · 5.4 days to cover
Days to cover
5.4d
Short-squeeze score
60 / 100
Insider activity
2 metricsNet insider buying (90D)
$246,654
Insider-sentiment score
83 / 100
Risk flags
1 metricsGoing concern
—